These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 23977668)
1. A report from the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (June 30-July 3, 2013 - Kuala Lumpur, Malaysia). Rabasseda X Drugs Today (Barc); 2013 Aug; 49(8):509-17. PubMed ID: 23977668 [TBL] [Abstract][Full Text] [Related]
2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Van Vaerenbergh K Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503 [TBL] [Abstract][Full Text] [Related]
3. Antiretroviral therapy and resistance to antiretroviral drugs. Lange JM; van Leeuwen R Ethiop Med J; 2002 Apr; 40 Suppl 1():51-75. PubMed ID: 12802831 [TBL] [Abstract][Full Text] [Related]
4. Short communication: low prevalence of genotypic drug resistance mutations among antiretroviral-naive HIV type 1 patients in Malaysia. Tee KK; Kamarulzaman A; Ng KP AIDS Res Hum Retroviruses; 2006 Feb; 22(2):121-4. PubMed ID: 16478392 [TBL] [Abstract][Full Text] [Related]
5. [Simplification of antiretroviral therapy: proposal for a score for the evaluation of patients with suppressed viremia]. Andreoni M Recenti Prog Med; 2014 Dec; 105(12):462-8. PubMed ID: 25533234 [TBL] [Abstract][Full Text] [Related]
6. Antiretroviral therapy and drug resistance in human immunodeficiency virus type 2 infection. Menéndez-Arias L; Alvarez M Antiviral Res; 2014 Feb; 102():70-86. PubMed ID: 24345729 [TBL] [Abstract][Full Text] [Related]
7. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial. Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E; Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227 [TBL] [Abstract][Full Text] [Related]
8. Prevalence and pattern of drug resistance mutations among antiretroviral-treated HIV-1 patients with suboptimal virological response in Malaysia. Tee KK; Kamarulzaman A; Ng KP Med Microbiol Immunol; 2006 Jun; 195(2):107-12. PubMed ID: 16404607 [TBL] [Abstract][Full Text] [Related]
9. [GESIDA/National AIDS Plan: Consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (Updated January 2015)]. Panel de expertos de GeSIDA y Plan Nacional sobre el Sida Enferm Infecc Microbiol Clin; 2015 Oct; 33(8):543.e1-43. PubMed ID: 25959461 [TBL] [Abstract][Full Text] [Related]
10. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. Hammer SM; Eron JJ; Reiss P; Schooley RT; Thompson MA; Walmsley S; Cahn P; Fischl MA; Gatell JM; Hirsch MS; Jacobsen DM; Montaner JS; Richman DD; Yeni PG; Volberding PA; JAMA; 2008 Aug; 300(5):555-70. PubMed ID: 18677028 [TBL] [Abstract][Full Text] [Related]
11. A multi-step pace towards a cure for HIV: kick, kill, and contain. López M AIDS Rev; 2013; 15(3):190-1. PubMed ID: 24002204 [TBL] [Abstract][Full Text] [Related]
12. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)]. Panel de expertos de Gesida y Plan Nacional sobre el Sida Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):e1-89. PubMed ID: 22633764 [TBL] [Abstract][Full Text] [Related]
13. PI/NRTI "sparing" regimens for HIV infection. IAPAC sessions 2001, July 18-19, 2001 - Chicago. Cohen C IAPAC Mon; 2001 Aug; 7(8):254-60. PubMed ID: 11708281 [No Abstract] [Full Text] [Related]
14. Scientific rationale for antiretroviral therapy in 2005: viral reservoirs and resistance evolution. Siliciano RF Top HIV Med; 2005; 13(3):96-100. PubMed ID: 16170226 [TBL] [Abstract][Full Text] [Related]
15. Targets for inhibition of HIV replication: entry, enzyme action, release and maturation. Sierra-Aragón S; Walter H Intervirology; 2012; 55(2):84-97. PubMed ID: 22286875 [TBL] [Abstract][Full Text] [Related]
16. Antiretroviral therapy for HIV: drug resistance and sequencing. Burkle WS J Assoc Nurses AIDS Care; 2002; 13(1):76-80. PubMed ID: 11828862 [No Abstract] [Full Text] [Related]
17. Response to efavirenz plus two nucleoside reverse-transcriptase inhibitors in patients with advanced stage human immunodeficiency virus-1 infection in Taiwan. Deng SC; Chen MY; Hsieh SM; Sheng WH; Hsiao CF; Hung CC; Chang SC J Microbiol Immunol Infect; 2003 Mar; 36(1):10-4. PubMed ID: 12741726 [TBL] [Abstract][Full Text] [Related]
18. [HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy]. Jambroes M; Weverling GJ; Reiss P; Danner SA; Jurriaans S; ten Veen JH; van der Ende ME; Schutten M; Schneider MM; Schuurman R; Mulder JW; Kroes AC; Lange JM; de Wolf F; Ned Tijdschr Geneeskd; 2001 Aug; 145(33):1591-7. PubMed ID: 11534377 [TBL] [Abstract][Full Text] [Related]
19. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Pierson T; McArthur J; Siliciano RF Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072 [TBL] [Abstract][Full Text] [Related]